Q4 2024 Earnings Call Transcript March 3, 2025 Ocular Therapeutix, Inc. misses on earnings expectations. Reported EPS is ...

Q4 2024 Earnings Call Transcript March 5, 2025 EyePoint Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.64 EPS, expectations were $-0.54. Tessa Romero – JPMorgan: Yigal ...

We sharpened our focus and embraced a single, bold mission: to redefine the retina experience. Today, disrupting the treatment paradigm in wet AMD is ... of vision loss and OCT changes.

Baseline angiographic lesion characteristics predictive of clinical responsePublished in peer-reviewed journal Ophthalmic Surgery, Lasers and ...

Zervimesine is an investigational oral, once-daily pill being developed for the treatment of CNS diseases, including ...

Announces several updates to enhance and accelerate AXPAXLI registrational program in wet AMD, potentially supporting label flexibility of 6-12 ...

Wet AMD is the leading cause of vision loss in the elderly, affecting around three million people in the US and Europe and driving a retinal disease market that is worth upwards of $18 billion a year.

George Elston; Chief Financial Officer, Executive Vice President; EyePoint Pharmaceuticals Inc Jay Duker; President, Chief Executive Officer; EyePoint Pharmaceuticals Inc Good morning. My name is ...

The data was included in the paper, titled “Sozinibercept Combination Therapy for Neovascular Age-Related Macular ...

AMD has made several key improvements to its core GPU architecture with RDNA 4. This includes a new compute unit design, which can run at higher clock speeds than before, and which AMD also says ...